Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pancreaskreft

Objectives

Norway’s national action programme for pancreatic cancer provides evidence-informed recommendations for diagnosis, treatment and follow-up, aiming to secure high-quality, equitable and coordinated public cancer care across the country.[1][2][3]It covers pancreatic ductal adenocarcinoma and selected periampullary malignancies with overlapping presentation and management, while rare pancreatic tumour types are largely outside its detailed scope.[2]The programme combines timely investigation, specialist treatment, rehabilitation, follow-up and palliative care within an individually adapted but predictable cancer pathway.[4][5]

• Identify suspected disease promptly, particularly in people with relevant symptoms, diabetes, chronic pancreatitis, smoking, overweight or possible hereditary susceptibility.[6][7]
• Establish diagnosis, tumour extent, metastatic status and resectability through appropriate imaging and multidisciplinary assessment.[7][8]
• Provide curative-intent surgery for appropriately selected patients with resectable disease, recognising surgery as the foundation of potentially curative treatment.[9][10]
• Improve postoperative outcomes and reduce recurrence through standardised pathology, suitable perioperative care and adjuvant chemotherapy where indicated.[11][12][13]
• Deliver palliative care that relieves symptoms, protects quality of life and, where possible, extends life for people with advanced or metastatic disease.[14]
• Support patients’ nutritional, functional, psychosocial and symptom-management needs throughout treatment and follow-up.[13][15][16][17]

Implementation

Implementation is based on national professional guidance developed and updated through systematic evidence review, multidisciplinary clinical expertise, consultation and evidence grading.[18][19][3]The Norwegian Directorate of Health has a coordinating and normative role, while regional health authorities are responsible for implementing cancer pathways and following up their target times; service owners and managers are expected to enable adherence to recommendations.[4][17][20]Recommendations are not directly legally binding, but significant departures should be documented and justified.[21][20]

• Deliver assessment and treatment through specialist centres with multidisciplinary teams, continuous relevant clinical cover, pancreatic surgery, pathology, oncology, anaesthesia, intensive care, endoscopy and radiological intervention capability.[22][23][24]
• Use pancreatic-protocol computed tomography with chest imaging as the principal diagnostic and staging method; use magnetic resonance imaging, endoscopic ultrasound with or without tissue sampling, and positron emission tomography-computed tomography selectively for specific diagnostic questions.[25][26][27]
• Refer people with suspected hereditary predisposition to centres offering clinical genetic counselling and possible genetic testing.[6][22]
• Apply pathway standards of 8 calendar days from referral receipt to first specialist attendance, 14 days from first attendance to completed investigation and decision, and 14 days from completed investigation to treatment, giving a total target of 36 days from referral to surgery or medicine treatment.[5]
• Assess resectability individually, including arterial and venous involvement and the feasibility of safe vascular reconstruction; major superior mesenteric artery or coeliac-axis involvement generally precludes resection.[28][9]
• Use pancreatoduodenectomy for most resectable pancreatic-head tumours and tailor treatment to comorbidity, general condition and patient preferences.[10][29]
• Handle surgical specimens through standardised orientation, dissection, sampling and reporting, including tumour type, size, location, margins, lymph-node status, invasion and pathological tumour-node-metastasis classification.[30][31][32]
• Define microscopic margin involvement using a tumour-to-surface distance of less than 1 millimetre and aim to provide pathology reports within two to three weeks after surgery.[12][32]
• Offer six months of adjuvant chemotherapy after radical surgery to eligible patients, generally starting within 12 weeks; gemcitabine plus capecitabine is identified as the standard regimen, with gemcitabine alone for patients unable to tolerate combination treatment.[33][13]
• Coordinate postoperative review, oncology follow-up during adjuvant therapy and subsequent general-practitioner follow-up, with attention to nutrition, enzyme replacement, diabetes, pain, functional status and late effects.[13][15][34]
• Avoid routine imaging, blood tests and fixed consultation intervals after primary treatment where there is no supporting evidence; investigate symptoms or findings suggestive of recurrence using appropriate imaging, blood tests and carbohydrate antigen 19-9 where relevant.[15][34]
• Manage advanced disease through symptom-directed and tumour-directed care, using systemic therapy according to functional status, bilirubin level, previous treatment, response and adverse effects.[35][36]
• Prefer less invasive palliation, including endoscopic stents for biliary or duodenal obstruction and coeliac plexus blockade for selected patients with difficult pain.[37][38][39]
• Assess nutritional status early and repeatedly, offer dietary counselling and oral supplements where appropriate, and favour enteral over intravenous nutrition.[16][40][17]
• Review the action programme annually and update it when necessary through working groups appointed by regional health authorities and the Directorate, supported by the Norwegian Knowledge Centre for the Health Services and the Norwegian Institute of Public Health.[41][42][43]

Monitoring & Evaluation

Monitoring and accountability combine national pathway time standards, clinical follow-up, structured pathology reporting, evidence grading and annual guideline review. Regional health authorities are responsible for implementing and following up the cancer pathways and their target times.[4]

• Track pathway timeliness from referral to first specialist appointment, completion of investigation and treatment initiation. For pancreatic cancer, the normative intervals are 8 calendar days from referral receipt to first appointment, 14 days to completed investigation and decision, 14 days to treatment, and 36 days overall from referral to surgery or medication treatment.[5]
• Review the national action programme annually and update it when necessary in response to rapid developments in cancer treatment. Updates may be prepared more frequently if the Norwegian Gastrointestinal Cancer Group or the working group identifies a need and contacts the Norwegian Directorate of Health.[42][43]
• Publish updated web versions through the Norwegian Directorate of Health and the Norwegian Electronic Health Library.[43]
• Use systematic literature searching, methodological support and transparent assessment of the knowledge base in guideline development and revision. The evidence base is classified from A to D, from systematic reviews and meta-analyses of randomised controlled trials to expert reports and clinical expertise.[18][19]
• Recognise that evidence grades describe the supporting evidence rather than the relative strength of recommendations, as cost-effectiveness, clinical judgement and ethical considerations were not explicitly assessed in this grading approach.[19]
• Monitor diagnostic and treatment processes through standardised assessment of tumour type, tumour-node-metastasis classification, vascular involvement, resectability and suspected recurrence. Computed tomography is the principal investigation for suspected recurrence, with pancreatic-protocol imaging recommended where locoregional recurrence is suspected.[44][27]
• Use carbohydrate antigen 19-9 to support monitoring of systemic chemotherapy response where relevant, but not for population screening or diagnosis because of its limited diagnostic value.[25][27]
• Assess systemic and palliative treatment continuously against radiological response, symptoms, adverse effects, functional status, tolerance and nutritional status; adjust dose intensity, duration or treatment breaks accordingly.[45][36][16]
• Undertake surgical follow-up approximately 4 to 6 weeks after curative-intent surgery, provide oncology follow-up during adjuvant chemotherapy, and subsequently transfer general follow-up to the general practitioner with information exchange between services.[13][15][34]
• Avoid routine imaging, specialised blood tests and fixed general-practice consultation intervals after primary treatment, as evidence of prognostic benefit is insufficient. Investigate new symptoms or findings suggestive of recurrence with appropriate imaging, blood tests and CA 19-9.[15][34]
• Report pathology systematically using standardised specimen handling and diagnostic templates. Reports should cover tumour origin, type, size, location, stage, margins, lymph-node status, vascular and perineural invasion, and additional resected structures.[31][32][46]
• Define microscopic margin involvement using a tumour-to-surface distance of less than 1 millimetre, and assess at least an average of 15 lymph nodes in pancreaticoduodenectomy specimens.[12]
• Provide pathology reports within two to three weeks after the procedure, while another section identifies a reporting aim of three to four weeks.[31][33]
• Document macroscopic pathological findings with overview and close-up images to support retrospective review.[30]

The material does not specify a unified national outcome-indicator set, routine audit process, public reporting schedule, surveillance system or formal accountability mechanism beyond pathway follow-up, clinical reporting requirements, evidence-based updating and the stated responsibilities of regional health authorities and service leaders.[4][20][42]

Costing & Financing

No programme budget, treatment-cost schedule, funding allocation, financing source, resource-mobilisation target, funding-gap estimate or formal economic assumption is specified.[17][41][42]

• Require specialist-centre capacity for diagnostic imaging, pancreatic surgery, endoscopic and radiological intervention, oncology, pathology, anaesthesia, intensive care and multidisciplinary working, but provide no monetary valuation of these resources.[22]
• Assign service owners and leaders responsibility for arranging services so national recommendations can be followed, without quantifying associated staffing or infrastructure costs.[20]
• Note that regional health enterprises were asked to release participating professionals during working hours for guideline development, but no cost or funding mechanism is reported.[3]
• Recognise that self-expanding metal stents cost more than plastic stents but provide better and more durable biliary drainage; no quantified comparison is provided.[37]
• Identify high costs, marginal clinical benefit and increased adverse effects as reasons why an erlotinib combination was not recommended in Norway.[35]

The source refers to costs when weighing selected clinical interventions, including pre-operative laparoscopy, but does not provide an economic evaluation methodology, cost-effectiveness threshold, monetary values or budget impact assessment.[47][48][49]